Dr Andrew Stephens is Head of the OCRF funded Ovarian Cancer Biomarkers Laboratory at the Hudson Institute of Medical Research. He provides leadership to the team and oversees the group’s research activities, aimed at the development of new diagnostic and therapeutic technologies for the early detection of ovarian cancer. He has substantial experience in the application of proteomic technologies to the discovery of new disease markers.
Dr Stephens completed his PhD in the department of Biochemistry at Monash University Australia. He held postdoctoral positions at the University of Sydney and at the Hudson Institute of Medical Research prior to taking up the position of OCRF Fellow in 2006.
Project: Measuring the “CXCL10 Active Ratio” as a Novel Diagnostic Approach to Ovarian Cancer; OCRF Tissue Bank – Hudson Institute